Servier Philippines

Servier is a global pharmaceutical group governed by a nonprofit foundation, committed to making a meaningful social impact for patients and contributing to a sustainable world. The Group’s unique governance model ensures its independence while fostering long-term innovation, with 100% of its profits reinvested in the company’s development. As a world leader in cardiometabolism and venous diseases, Servier drives transformative innovation in chronic conditions through a holistic approach, making patient adherence a priority across the globe. Its ambition is to become a leading player in rare cancers, which is why the Group invests heavily in oncology, allocating close to 70% of its R&D budget to this field. By leveraging precision medicine, Servier develops therapies that are more targeted and more effective. Bolstered by its success in oncology, Servier has expanded into neurology, a key driver of future growth. The Group focuses on a select number of neurodegenerative diseases, where accurate patient profiling enables targeted therapeutic responses through precision medicine. To further enhance access to high-quality, affordable care, Servier also provides an extensive range of generic medicines, building on well-established brands in France, Eastern Europe, and Brazil. In all its activities and at every stage of the medicine life cycle, the Group integrates the patient’s voice. Headquartered in France, Servier operates in close to 140 countries. In 2023-2024, the Group, which employs over 22,000 people worldwide, achieved sales revenue of €5.9 billion. To report a suspected adverse event with a Servier drug, please visit https://servier.com.ph/contact-us/#report-a-side-effect